Compass Pathways 株価情報 (NASDAQ: CMPS)

最新ニュース Compass Pathways (NASDAQ:CMPS) 株価情報

Compass Pathways

Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.

COMPASS Pathways Plc - American Depository Shares

Compass Pathways PLC

COMPASS Pathways plc (CMPS) Q3 2024 Earnings Call Transcript

Compass Pathways Plc ( ($CMPS) ) has released its Q3 earnings. Here is a breakdown of the information Compass Pathways Plc presented to its investo...

Compass Pathways Focuses on Key Psilocybin Program

Ritu Baral, an analyst from TD Cowen, maintained the Buy rating on COMPASS Pathways (CMPS – Research Report). The associated price target remains t...

Strategic Foresight and Proactive Measures Underpin Buy Rating for COMPASS Pathways

RBC Capital lowered the firm's price target on Compass Pathways (CMPS) to $18 from $23 but keeps an Outperform rating on the shares after its Q3 re...

Compass Pathways price target lowered to $18 from $23 at RBC Capital

H.C. Wainwright lowered the firm's price target on Compass Pathways (CMPS) to $60 from $120 and keeps a Buy rating on the shares. The company repor...

Compass Pathways price target lowered to $60 from $120 at H.C. Wainwright

Compass Pathways (CMPS) announced yesterday morning with earnings that as a result of changing timelines for its Phase 3 trials, it will be reducin...

Compass Pathways cuts 30% of workforce on Phase 3 trial delays

Compass Pathways: Minor Delay Of COMP360 Data Brings About Buy Opportunity

Compass Pathways: No Near-Term Fix For Struggling Psychedelic Therapy Pioneer

Compass Pathways: Phase 3 Trial Delay - Both Understandable And Disappointing

In a report released yesterday, Thomas Shrader from BTIG maintained a Buy rating on COMPASS Pathways (CMPS – Research Report), with a price target ...

BTIG Keeps Their Buy Rating on COMPASS Pathways (CMPS)

CMPS

Earnings

Health Care

Press Releases

Compass Pathways Announces First Quarter 2024 Financial Results and Business Highlights

News

Compass Pathways to participate in upcoming H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

Management

Compass Pathways appoints Lori Englebert as Chief Commercial Officer

Compass Pathways to announce second quarter financial results on August 1, 2024

Compass Pathways announces second quarter 2024 financial results and business highlights

COMPASS Pathways to participate in Canaccord Genuity 44th Annual Growth Conference

Compass Pathways to participate in three investor conferences in September

Compass Pathways to Participate in Cowen Psychedelics and Novel Mechanisms in Neuropsychiatry Summit

Compass Pathways to Announce Third Quarter Financial Results on October 31, 2024

Compass Pathways Announces Third Quarter 2024 Financial Results and Business Updates

COLL

Akebia Therapeutics

Aldeyra Therapeutics, Inc. - Common Stock

Aldeyra Therapeutics

Biomea Fusion

Design Therapeutics

Fate Therapeutics

4D Molecular Therapeutics, Inc. - Common Stock

4D Molecular Therapeutics

Genfit

Inozyme Pharma

ITeos Therapeutics

Jasper Therapeutics, Inc. - Class A Common Stock

Jasper Therapeutics

Lexeo Therapeutics

Lyell Immunopharma

Ocugen

Organogenesis Hldgs

AVITA Medical

Rezolute

Sage Therapeutics

Sangamo Therapeutics, Inc. - Common Stock

Sangamo Therapeutics

Sutro Biopharma

Taysha Gene Therapies, Inc. - Common Stock

Taysha Gene Therapies

Tevogen Bio Holdings

Vanda Pharmaceuticals Inc. - Common Stock

Vanda Pharma

Voyager Therapeutics, Inc. - Common Stock

Voyager Therapeutics

XOMA Royalty

Zura Bio Limited - Class A Ordinary shares

Comments

Compass Pathways

ニュース

最新ニュース Compass Pathways (NASDAQ:CMPS) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル